Monopar Therapeutics Inc.
NASDAQTotal Valuation
Monopar Therapeutics Inc. carries a market capitalization of 485.16M, placing it among publicly traded companies globally. Its enterprise value stands at 487.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 485.16M |
| Enterprise Value | 487.29M |
Share Statistics
Monopar Therapeutics Inc. currently has 6.71M shares outstanding.
| Shares Outstanding | 6.71M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 4.75 |
| P/TBV Ratio | 4.75 |
| P/FCF Ratio | -61.32 |
| P/OCF Ratio | -61.32 |
Financial Position
Monopar Therapeutics Inc. maintains a current ratio of 33.56, meaning it holds 33.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 33.56 |
| Quick Ratio | 33.44 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -19.50 |
| Return on Assets (ROA) | -18.90 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Monopar Therapeutics Inc.'s stock has declined approximately -6.31238% over the past 52 weeks. The 50-day moving average sits at 98.91, while the 200-day moving average is 76.91.
| Beta (5Y) | N/A |
| 52-Week Price Change | -6.31238% |
| 50-Day Moving Average | 98.91 |
| 200-Day Moving Average | 76.91 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -22.12M, while operating income came in at -22.12M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -22.12M |
| Pretax Income | -17.84M |
| Net Income | -17.84M |
| EBITDA | -22.12M |
| EBIT | -22.12M |
| Earnings Per Share (EPS) | -2.21 |
Balance Sheet
Monopar Therapeutics Inc. holds 134.30M in cash and equivalents against 107,829.00 in total debt, resulting in a net debt position of -52.76M. Total book value stands at 130.85M, with working capital of 130.75M providing operational flexibility.
| Cash & Cash Equivalents | 134.30M |
| Total Debt | 107,829.00 |
| Net Debt | -52.76M |
| Equity (Book Value) | 130.85M |
| Book Value Per Share | 19.50 |
| Working Capital | 130.75M |
Cash Flow
Monopar Therapeutics Inc. produced -12.18M in operating cash flow over the past twelve months.
| Operating Cash Flow | -12.18M |
| Capital Expenditures | N/A |
| Free Cash Flow | -12.18M |
| FCF Per Share | -1.51 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -14.67 |
| FCF Yield | -1.63 |
Stock Splits
Monopar Therapeutics Inc.'s most recent stock split took place on August 13, 2024 with a 5:1 split ratio.
| Last Split Date | 8/13/2024 |
| Split Ratio | 5:1 |
Scores
Monopar Therapeutics Inc. posts an Altman Z-Score of 90.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 90.02 |